{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Koh J"],"funding":["Ministry of Health and Welfare"],"pagination":["443-456"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12016828"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["57(2)"],"pubmed_abstract":["Purpose
Considering the high disease burden and unique features of Asian patients with breast cancer (BC), it is essential to have a comprehensive view of genetic characteristics in this population. An institutional targeted sequencing platform was developed through the Korea Research-Driven Hospitals project and was incorporated into clinical practice. This study explores the use of targeted next-generation sequencing (NGS) and its outcomes in patients with advanced/metastatic BC in the real world.Materials and methods
We reviewed the results of NGS tests administered to BC patients using a customized sequencing platform-FiRST Cancer Panel (FCP)-over 7 years. We systematically described clinical translation of FCP for precise diagnostics, personalized therapeutic strategie"],"journal":["Cancer research and treatment"],"pubmed_title":["Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience."],"pmcid":["PMC12016828"],"funding_grant_id":["HR14C0003"],"pubmed_authors":["Lee S","Kim TY","Kim JI","Seo J","Yun H","Kwon SY","Song MG","Lee DW","Seong MW","Kim J","Choi J","Jeon YK","Kim M","Won JK","Lee JS","Kim S","Ryu HS","Yi H","Woo GU","Bae JM","Koh J","Kim JH","Im SA","Lee KH"],"additional_accession":[]},"is_claimable":false,"name":"Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience.","description":"Purpose
Considering the high disease burden and unique features of Asian patients with breast cancer (BC), it is essential to have a comprehensive view of genetic characteristics in this population. An institutional targeted sequencing platform was developed through the Korea Research-Driven Hospitals project and was incorporated into clinical practice. This study explores the use of targeted next-generation sequencing (NGS) and its outcomes in patients with advanced/metastatic BC in the real world.Materials and methods
We reviewed the results of NGS tests administered to BC patients using a customized sequencing platform-FiRST Cancer Panel (FCP)-over 7 years. We systematically described clinical translation of FCP for precise diagnostics, personalized therapeutic strategie","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2025-07-02T03:04:59.876Z","creation":"2025-07-02T03:04:59.876Z"},"accession":"S-EPMC12016828","cross_references":{"pubmed":["39164082"],"doi":["10.4143/crt.2024.296"]}}